Starting point for benchmarking outcomes and reporting of pituitary adenoma surgery within the European Reference Network on Rare Endocrine Conditions (Endo-ERN): results from a meta-analysis and survey study
Author:
Zamanipoor Najafabadi Amir H123ORCID, van der Meulen Merel2, Priego Zurita Ana Luisa2, Faisal Ahmed S4ORCID, van Furth Wouter R1, Charmandari Evangelia5, Hiort Olaf6, Pereira Alberto M7, Dattani Mehul8ORCID, Vitali Diana9, de Graaf Johan P10, Biermasz Nienke R11, _ _, Steenvoorden D, Bowring I, van der Klauw MM, Vergeer RA, Losa M, Mortini P, Drake W, Grieve J, Didi M, Mallucci C, Shaikh MG, Hassan S, Jorgensen JOL, Albarazi M, Zaharieva S, Hadzhiyanev A., Tóth M, Sípos L, Unuane D, D'Haens J, Feldt-Rasmussen U, Poulsgaard L, Brue T, Dufour H, Bertherat J, Gaillard S, Karavitaki N, Ahmed S, Unger N, Kreitschmann-Andermahr I, Gaztambide S, Pomposo I, Gan H-W, Dorward N, Fliers E, Hoogmoed J, Scaroni C, Denaro L, Nordenström A, Olsson M, Zilaitiene B, Tamašauskas A, Persani L, Lasio G, Maiter D, Raftopoulos C, Volke V, Rätsep T, Matarazzo P, Peretta P, Deutschbein T, Perez J, Zucchini S, Mazzatenta D, Grottoli S, Zenga F, Devuyst F, De Witte O, Gatto F, Rossi D, Schilbach K, Rachinger W, Beckers A, Martin D, Al-Mrayat M, Mathad N, Neggers SJCMM, Dallenga AHG, Lebl J, Tichy M, Reincke MM, van de Ven AC, van Lindert E, Kotnik P, Bošnjak R, Biagetti B, Cordero E, Colao A, Cappabianca P
Affiliation:
1. Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands 2. Department of Medicine, Division of Endocrinology and Centre for Endocrine Tumors, Leiden University Medical Centre, Leiden, The Netherlands 3. Department of Neurosurgery, University Neurosurgical Centre Holland (UNCH), Leiden University Medical Centre, Haaglanden Medical Centre and Haga Teaching Hospitals, Leiden and The Hague, The Netherlands 4. Chair of Work Package of E-Health & ICT of Endo-ERN, Developmental Endocrinology Research Group, School of Medicine, Dentistry & Nursing, University of Glasgow and Office for Rare Conditions, Royal Hospital for Children & Queen Elizabeth University Hospital, Glasgow, UK 5. Pediatric Chair Main Thematic Group 6 Pituitary of Endo-ERN, Division of Endocrinology, Metabolism and Diabetes, First Department of Pediatrics, National and Kapodistrian University of Athens Medical School, ‘Aghia Sophia’ Children’s Hospital, Athens, Greece 6. Pediatric Chair and Deputy Coordinator of Endo-ERN, Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics and Adolescent Medicine, University of Lübeck, Lübeck, Germany 7. Adult Chair and Coordinator of Endo-ERN, Department of Endocrinology and Metabolism, Amsterdam University Medical Center, Amsterdam, The Netherlands 8. London Centre for Pediatric Endocrinology and Diabetes at Great Ormond Street Children's Hospital and University College London Hospitals, London, UK 9. SOD ITALIA (Italian Organization for Septo Optic Dysplasia and other Neuroendocrine Disorders), European Patient Advocacy Group, Rome, Italy 10. Dutch Pituitary Foundation, European Patient Advocacy Group, Nijkerk, The Netherlands 11. Adult Chair Main Thematic Group 6 Pituitary of Endo-ERN, Department of Medicine, Division of Endocrinology and Centre for Endocrine Tumors, Leiden University Medical Centre, Leiden, The Netherlands
Abstract
Objective
The European Reference Network on Rare Endocrine Conditions (Endo-ERN) aims to organize high-quality healthcare throughout Europe, including care for pituitary adenoma patients. As surgery is the mainstay of treatment, we aimed to describe the current surgical practice and published surgical outcomes of pituitary adenoma within Endo-ERN.
Design and Methods
Systematic review and meta-analysis of studies reporting surgical outcomes of pituitary adenoma patients within Endo-ERN MTG6 pituitary reference centers between 2010 and 2019. A survey was completed by reference centers on their current surgical practice.
Results
A total of 18 out of 43 (42%) reference centers located in 7 of the 20 (35%) MTG6-represented countries published 48 articles. Remission rates were 50% (95% CI: 42–59) for patients with acromegaly, 68% (95% CI: 60–75) for Cushing’s disease, and 53% (95% CI: 39–66%) for prolactinoma. Gross total resection was achieved in 49% (95% CI: 37–61%) of patients and visual improvement in 78% (95% CI: 68–87). Mortality, hemorrhage, and carotid injury occurred in less than 1% of patients. New-onset hypopituitarism occurred in 16% (95% CI: 11–23), transient diabetes insipidus in 12% (95% CI: 6–21), permanent diabetes insipidus in 4% (95% CI: 3–6), syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in 9% (95% CI: 5–14), severe epistaxis in 2% (95% CI: 0–4), and cerebrospinal fluid leak in 4% (95% CI: 2–6). Thirty-five (81%) centers completed the survey: 54% were operated endoscopically and 57% were together with an ENT surgeon.
Conclusion
The results of this study could be used as a first benchmark for the outcomes of pituitary adenoma surgery within Endo-ERN. However, the heterogeneity between studies in the reporting of outcomes hampers comparability and warrants outcome collection through registries.
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|